LONDON – A new method of probing the mechanisms of drug resistance in unicellular parasites has identified a tranche of genes and proteins that may make it possible to develop new treatments for hitherto difficult-to-treat infections.
Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round last week to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications.
Transgene SA is ramping up its engagement with China by establishing a wholly owned subsidiary called Transgene Biopharmaceuticals Technology (Shanghai) Co. Ltd., which will serve as a vehicle for its scientific collaboration with local academic research groups.
LONDON – For once "unprecedented" was the mot juste as the CEOs of nine pharma and biotech companies took to the stage with government health and overseas aid ministers, and the heads of agencies including the World Health Organization (WHO) and the World Bank, to back the London Declaration, pledging to control or eliminate 10 neglected tropical diseases (NTDs) by 2020.
• Circadian Technologies Ltd., of Melbourne, Australia, said preclinical data showed that VEGF-C blockade, through administration of Circadian's lead candidate VGX-100, a human antibody, significantly improved corneal graft survival in an animal model.
Shares in Orexo AB fell more than 10 percent Tuesday on news that the Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc., was terminating an alliance to develop drugs targeting pathways involved in arachidonic acid metabolism.
LONDON – There's been another twist in the gene therapy saga, with the European Commission refusing to give its usual rubber stamp to the European Medicines Agency's (EMA) decision not to grant marketing authorization to Glybera, a treatment for inherited disorder lipoprotein lipase deficiency (LPL).
LONDON – Blocking a receptor molecule on natural killer (NK) cells in mice can protect the animals from serious viral infections that would normally kill them, researchers have shown.
LONDON – BTG plc is celebrating its first regulatory approval after the FDA gave the nod to Voraxaze, an antidote to the chemotherapeutic methotrexate.
Shares in 4SC AG surged more than 38 percent last week on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).
RSS